Echo(1) | $15,000,000 | (Aug 1, 2025)
KredosAi | Undisclosed Amount | (Aug 1, 2025)
Cline | $32,000,000 | (Aug 1, 2025)
Certified by Founder
Lodge
Bolden Therapeutics
start up
United States
- Providence, Rhode Island
- 10/01/2024
- Unknown
- Undisclosed Amount
Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.
- Industry Biotechnology Research
- Website https://www.boldentherapeutics.com/
- LinkedIn https://www.linkedin.com/company/bolden-therapeutics/about/
Moonshine AI | Undisclosed Amount | (Aug 1, 2025)
Noma Security | $100,000,000 | (Aug 1, 2025)
Anaconda, Inc. | $150,000,000 | (Aug 1, 2025)
Nebulock | $8,500,000 | (Aug 1, 2025)
MyPrize | $21,000,000 | (Aug 1, 2025)
Safe Security | $70,000,000 | (Aug 1, 2025)
Merso | $3,000,000 | (Aug 1, 2025)
Metaforms | $9,000,000 | (Aug 1, 2025)
Ultromics | $55,000,000 | (Jul 31, 2025)